US.CRL · Charles River Laboratories

{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.3,
      "details": {
        "atrPct": 4.318151547615601,
        "turnoverUsdM": 283.997751,
        "liquidityPoints": 0.6,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.6,
    "stopLevels": {
      "symbol": "US.CRL",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 315.5428,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 3,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.5,
      "stop_loss_percent": 8.6,
      "take_profit_price": 389.1166,
      "target_multiplier": 2.2,
      "technical_strength": 2,
      "take_profit_percent": 12.7
    },
    "positionPoints": 1.3,
    "stopLossPoints": 1.2,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.470536624289239,
    "stopLossPercent": 8.636303095231202,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 80.9,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 57.9,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 23
  },
  "market": {
    "ma20": 306.652,
    "ma50": 293.9442,
    "close": 345.37,
    "prevClose": 339.66,
    "avgVolume20": 1090005,
    "volumeRatio": 0.75,
    "changePercent": 1.68
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 23,
    "details": {
      "ret_5d": 0.1506580426672679,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 23,
      "vcp_bonus": 2,
      "vol_ratio": 0.7538469295611956,
      "ret_points": 18,
      "vol_points": 0,
      "range_ratio": 1.0521357797380089,
      "volat_points": 0,
      "day_range_pct": 0.04351854532819883,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 80.9,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 1.5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 30,
        "contribution": 1.5
      },
      {
        "raw": 16.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 82,
        "contribution": 16.4
      },
      {
        "raw": 3.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 24,
        "contribution": 3.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.1,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 61,
        "contribution": 6.1
      },
      {
        "raw": 22.3,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 74.33,
        "contribution": 22.3
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "觀望",
    "result": 57.9,
    "details": [
      "基本面分析總分: 1.5/5分",
      "資金流分析總分: 16.4/20分",
      "市場環境分析總分: 3.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.1/10分",
      "技術信號分析總分: 22.3/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 1.5,
      "資金流": 16.4,
      "市場環境": 3.6,
      "情緒分析": 6,
      "技術信號": 22.3,
      "風險管理": 6.1
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 6,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 283.997751,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0,
          "marketCapPoints": 0.4
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "優秀",
        "items": {
          "cmfPoints": 2.4,
          "mfiPoints": 4,
          "obvPoints": 4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.CRL",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 735.23500335,
                "ma50": 725.8121993399999,
                "name": "QQQ",
                "close": 704.40002,
                "points": 0.4
              },
              "spy": {
                "ma20": 770.1504974000001,
                "ma50": 767.8083956999998,
                "name": "SPY",
                "close": 759.96997,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 4.318151547615601,
          "atrPoints": 2,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 6,
              "negativeHits": 0,
              "positiveHits": 3,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 143102846,
                "url": "https://finnhub.io/api/news?id=5ea2f32a7bb66a27e2e514c69e83b7db49e2482b92d84521e71f0668f2fc0711",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International (CRL) drew fresh investor attention after announcing a collaboration with Magellan Stem Cells focused on stem cell therapies and regenerative medicine, supported by biologics quality control and cGMP viral testing. For context, Charles River Laboratories International has seen strong momentum build through 2026, with the share price at US$344.87 after a 1-day share price return of 9.33%, a 30-day share price return of 23.60% and a year-to-date share...",
                "category": "company",
                "datetime": 1792678267,
                "headline": "Charles River Laboratories International (CRL) Partners With Magellan As Valuation Questions Linger"
              },
              {
                "id": 142948227,
                "url": "https://finnhub.io/api/news?id=79f0a13d734af94e39735179cc832b22a1bdfab53f0be68fd4b4623bb8fef809",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Wrapping up Q2 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Charles River Laboratories (NYSE:CRL) and its peers.",
                "category": "company",
                "datetime": 1792163259,
                "headline": "Drug Development Inputs & Services Stocks Q2 In Review: Charles River Laboratories (NYSE:CRL) Vs Peers"
              },
              {
                "id": 142697487,
                "url": "https://finnhub.io/api/news?id=37c828691300a9de678d26bd8593aede8f0b62d682cd1ebd6b5c9150950f1f69",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "PGNY vs. CRL: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1791384004,
                "headline": "PGNY or CRL: Which Is the Better Value Stock Right Now?"
              },
              {
                "id": 142592897,
                "url": "https://finnhub.io/api/news?id=73d6aea502d0d31bd3b4f84722916a1926fcbb56cee537a66e1d38055c72cb31",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Price targets for Charles River Laboratories International have shifted higher in recent research, with several firms now pointing to a range between US$219 and US$340, alongside a new fair value estimate of US$305. That cluster of higher targets aligns with more constructive analyst commentary after the company’s investor and analyst days, as firms factor in the updated long range plan and revised margin goals. As you read on, you will see how to track these changes and what to watch as the...",
                "category": "company",
                "datetime": 1790967988,
                "headline": "Charles River Laboratories (CRL) Stock Fair Value Rises After Analyst Day Target Increases"
              },
              {
                "id": 142499581,
                "url": "https://finnhub.io/api/news?id=7f51eba51258fdf6cd630123ee9af8f152c141f938e9c8148006d4aee3dc5cd2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Cooke & Bieler, an investment management firm, released its second-quarter investor letter for “Mid Cap Value Equity Strategy.” The letter can be downloaded here. U.S. equities rallied significantly in Q2, driven by shifting geopolitical risks and strong investor appetite for high-beta stocks, particularly in the tech sector, contributing to the S&P 500® and Nasdaq’s best […]",
                "category": "company",
                "datetime": 1790698275,
                "headline": "Demand Stabilization Fuels Charles River Laboratories International’s (CRL) Recovery"
              },
              {
                "id": 142402006,
                "url": "https://finnhub.io/api/news?id=42da75f3364248802af2056a822959beeb514891c450db0e2602056cc50c92c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International has seen its share price move sharply over the past year, and that kind of run naturally raises a question for you as an investor. Are the cash flows that the business can generate enough to support where the stock now trades? The stock has returned 102.3% over the past 12 months, which puts real pressure on the case that its current valuation can still be explained by its underlying cash generation. Recent moves to expand outsourced services in areas...",
                "category": "company",
                "datetime": 1790316582,
                "headline": "Charles River Laboratories (CRL) Stock Still Seems Reasonable Despite Rapid Cell Banking Launch"
              }
            ],
            "raw_source": [
              {
                "id": 143162853,
                "url": "https://finnhub.io/api/news?id=2db318dc4a25c97d1a7494bbdf5136a328c2c69f069372f18733503ae2f3c653",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/attachment/image/219ce2e9e505d26ba97bb843a7c37b56.png?io=w640",
                "source": "SeekingAlpha",
                "related": "CRL",
                "summary": "Wall Street weekly recap: hotter CPI, rising VIX, tech weakness and big bank earnings.",
                "category": "company",
                "datetime": 1792829457,
                "headline": "Wall Street Breakfast: What Moved Markets This Week"
              },
              {
                "id": 143136808,
                "url": "https://finnhub.io/api/news?id=9ba9375d9d0048b5a9d6928bd6e0a45d3fc8daaea86e66f9976860aec816cdcc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 33.8% over the past six months, topping the S&P 500 by 24.7 percentage points.",
                "category": "company",
                "datetime": 1792784679,
                "headline": "2 healthcare stocks to keep an eye on and 1 that underwhelm"
              },
              {
                "id": 143133938,
                "url": "https://finnhub.io/api/news?id=15716f0eee0e91f447d4c5c7f3391137b64c2f1b2c3e6b1c73e036d600fc389f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "New Report puts the market at $66.3bn in 2025, with oncology accounting for 38.3% and North America just over half, though patchy insurer coverage and infrastructural barriers remain stubborn obstacles for IQVIA, ICON, Medpace and Charles River LaboratoriesDublin, Oct. 23, 2026 (GLOBE NEWSWIRE) -- \"Clinical Trials Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035\" has been added to ResearchAndMarkets.com's offering. Clinical trials remain integral to drug develo",
                "category": "company",
                "datetime": 1792761360,
                "headline": "Global Clinical Trials Market Size, Share, Growth Trends, and Forecast, 2026-2035 | Clinical Trials Market set to more than Double to $144.4bn as Drugmakers Lean on Outside Researchers"
              },
              {
                "id": 143104329,
                "url": "https://finnhub.io/api/news?id=3896a60e2b5d9ce38dff6d623211f3edb4d2fc15727592911ab7a8454908f626",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "WILMINGTON, Mass., October 22, 2026--Charles River announced a collaboration with the U.S. FDA and Labcorp to develop screening tools to quantify and rank the abuse potential of new drugs",
                "category": "company",
                "datetime": 1792701000,
                "headline": "Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment"
              },
              {
                "id": 143104298,
                "url": "https://finnhub.io/api/news?id=5acfbfa9a14cd41ea2bd4040ab3e0ec95a82641a2a8cbd39263b0f43899edecf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the U.S. Food and Drug Administration (FDA) and Charles River Laboratories to advance the science used to evaluate a medicine's abuse potential, or the likelihood that it could be abused. The research aims to support safer drug development and more informed regulatory decisions.",
                "category": "company",
                "datetime": 1792701000,
                "headline": "Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential"
              },
              {
                "id": 143103433,
                "url": "https://finnhub.io/api/news?id=3d97b8ed77eb9eb9e0e5b699486d2fda3bb53b2e93fffa5512ec58eb04929c06",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.",
                "category": "company",
                "datetime": 1792691393,
                "headline": "3 mid-cap stocks walking a fine line"
              },
              {
                "id": 143133208,
                "url": "https://finnhub.io/api/news?id=5ad5a2a6a4690c69da2fcdd364a853f757380e418341c8d162006d91014da380",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Joint research effort seeks to improve abuse potential assessment tools to support drug development and public health decision-makingCharles River Laboratories International, Inc. (NYSE:CRL) today announced a Research",
                "category": "company",
                "datetime": 1792686992,
                "headline": "Charles River Laboratories Announces Research Collaboration Agreement With FDA And Labcorp For Developing Sensitive Screening Tools To Quantify And Rank Abuse Potential Of New Drugs"
              },
              {
                "id": 143102846,
                "url": "https://finnhub.io/api/news?id=5ea2f32a7bb66a27e2e514c69e83b7db49e2482b92d84521e71f0668f2fc0711",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International (CRL) drew fresh investor attention after announcing a collaboration with Magellan Stem Cells focused on stem cell therapies and regenerative medicine, supported by biologics quality control and cGMP viral testing. For context, Charles River Laboratories International has seen strong momentum build through 2026, with the share price at US$344.87 after a 1-day share price return of 9.33%, a 30-day share price return of 23.60% and a year-to-date share...",
                "category": "company",
                "datetime": 1792678267,
                "headline": "Charles River Laboratories International (CRL) Partners With Magellan As Valuation Questions Linger"
              },
              {
                "id": 143087275,
                "url": "https://finnhub.io/api/news?id=03f1395faaf1ce153aa8663ed2fb43ca91d55ee324ae7eadc3091391898f4941",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "CRL",
                "summary": "S&P 500 top movers on Oct. 21, 2026: CRL, SMCI and BE led gainers, while T, CMG and DXCM led decliners in the US session.",
                "category": "company",
                "datetime": 1792609569,
                "headline": "S&P 500 Top Movers: Oct. 21, 2026 US Session"
              },
              {
                "id": 143101331,
                "url": "https://finnhub.io/api/news?id=ef3a0807e6ba408cc266debfce606a68aaa42f84ee54709b3eef5839832c9624",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_4.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 4.33% on an annualized basis producing an average annual return of 17.1%. Currently, Charles River has a market capitalization of $15.34",
                "category": "company",
                "datetime": 1792606531,
                "headline": "$1000 Invested In Charles River 15 Years Ago Would Be Worth This Much Today"
              },
              {
                "id": 143087269,
                "url": "https://finnhub.io/api/news?id=e2c12db8e0def243d28efc6e5dc8649bede831bd251ec679d9ab82d85e6f4247",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "CRL",
                "summary": "S&P 500 top movers for Oct. 21, 2026: Supermicro rose 9.18% among gainers, while Dexcom fell 6.22% among losers.",
                "category": "company",
                "datetime": 1792600602,
                "headline": "S&P 500 Top Movers on Oct. 21, 2026: Supermicro Leads Gainers, Dexcom Leads Losers"
              },
              {
                "id": 143099646,
                "url": "https://finnhub.io/api/news?id=40a002bac31f89e89aeb12faf4369cb5c13b8e81859c5403ce5c45d49494b244",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/21/Big-Heavy-Rocket-space-Launch-System-Lau.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "SpaceX's blowout third quarter and Super Micro's guidance hike revive the AI trade, lifting the Nasdaq 100 as Netflix and AT&T slide on results.",
                "category": "company",
                "datetime": 1792587739,
                "headline": "SpaceX Jumps 10%, Nasdaq 100 Rises as AI Trade Returns: Stock Market Today"
              },
              {
                "id": 143031687,
                "url": "https://finnhub.io/api/news?id=9767c866ea027121f6e583a1c9d55c71caf1930dcf32f3011cf51a1089f09880",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "CRL",
                "summary": "S&P 500 top movers today: Equifax and Hasbro gained over 10%, while General Motors and DaVita fell more than 7% in a mixed session.",
                "category": "company",
                "datetime": 1792523164,
                "headline": "S&P 500 Top Movers: EFX and HAS Lead Today's Gainers, GM and DVA Fall"
              },
              {
                "id": 143032118,
                "url": "https://finnhub.io/api/news?id=5706a549de19317028a89a3d0711c22462e81539f7468dfc667f38a79817cba4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "The S&P 500 Health Care Sector was on track to set a fresh closing high, leading Tuesday's broad market gains.",
                "category": "company",
                "datetime": 1792521676,
                "headline": "The Healthcare Sector Nears a New High. These Stocks Are Leading the Charge."
              },
              {
                "id": 143031680,
                "url": "https://finnhub.io/api/news?id=e11728fc8f5fa19627c71da56097d365124708caa38ac808ec39585063e67696",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "CRL",
                "summary": "S&P 500 top movers for today's US session: Equifax led gainers at 11.46%, while General Motors led losers at -7.72%, ranked by percentage change.",
                "category": "company",
                "datetime": 1792514161,
                "headline": "S&P 500 Top Movers: Gainers and Losers From Today's US Session"
              },
              {
                "id": 143003297,
                "url": "https://finnhub.io/api/news?id=f1acfd41fd9b527a19736eca9f01d8234fd7f6f03163c95fadf8b26091f93997",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "The global clinical trial management services market is projected to grow from $36.2 billion in 2025 to $68.4 billion by 2033, a new Research and Markets report finds, with North America holding 34.7%; high service costs and strict regulation remain hurdles for IQVIA, ICON, Medpace and Charles River Laboratories.Dublin, Oct. 19, 2026 (GLOBE NEWSWIRE) -- \"Clinical Trial Management Services Market Size, Share & Trends Analysis Report 2026-2033\" has been added to ResearchAndMarkets.com's offering.",
                "category": "company",
                "datetime": 1792404180,
                "headline": "Clinical Trial Management Services Market Size, Share, Trends, and Forecast, 2026-2033 | Drugmakers' Outsourcing Push Lifts Clinical Trial Management Toward $68 Billion"
              },
              {
                "id": 142948227,
                "url": "https://finnhub.io/api/news?id=79f0a13d734af94e39735179cc832b22a1bdfab53f0be68fd4b4623bb8fef809",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Wrapping up Q2 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Charles River Laboratories (NYSE:CRL) and its peers.",
                "category": "company",
                "datetime": 1792163259,
                "headline": "Drug Development Inputs & Services Stocks Q2 In Review: Charles River Laboratories (NYSE:CRL) Vs Peers"
              },
              {
                "id": 142944401,
                "url": "https://finnhub.io/api/news?id=5421d801a102802a5e484c0529471ffad3f61138737e42180b93aaa13d80796c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Moby summary of State Street Corporation's Q3 2026 earnings call",
                "category": "company",
                "datetime": 1792067400,
                "headline": "State Street Corporation Q3 2026 Earnings Call Summary"
              },
              {
                "id": 142918192,
                "url": "https://finnhub.io/api/news?id=ae660821716f3ea046ae6c39fc8c801e40c2138288b6e40e46dd199a41500235",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Charles River (NYSE:CRL) has outperformed the market over the past 20 years by 1.14% on an annualized basis producing an average annual return of 10.15%. Currently, Charles River has a market capitalization of $15.44",
                "category": "company",
                "datetime": 1791978333,
                "headline": "Here’s How Much You Would Have Made Owning Charles River Stock In The Last 20 Years"
              },
              {
                "id": 142881848,
                "url": "https://finnhub.io/api/news?id=d92b840d57c7cf26fe9122c59c96eb5effa81ac8761ad4ac4bb9f698ce01fff4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "The partnership focuses on biologics quality control as well as viral and release testing under cGMP standards.",
                "category": "company",
                "datetime": 1791973542,
                "headline": "Charles River partners with Magellan Stem Cells on cell therapy"
              },
              {
                "id": 142872378,
                "url": "https://finnhub.io/api/news?id=62738761f42c073d33babe49d64f521c4f661034a6934bafccd6cd78abbca7c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Outsource clinical trials and leverage AI, decentralized models and regulatory expertise to cut costs, accelerate drug development and expand patient access.Dublin, Oct. 14, 2026 (GLOBE NEWSWIRE) -- \"Healthcare Contract Research Organization (CRO) - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering. Global Healthcare Contract Research Organization (CRO) Market to Reach US$63.3 Billion by 2032 The global Healthcare Contract Research Organization (CRO) market, e",
                "category": "company",
                "datetime": 1791965460,
                "headline": "Healthcare Contract Research Organization (CRO) - Global Strategic Business Report: Secure Share of US$63.3 Billion Market by 2032 as IQVIA, ICON, Charles River, and Syneos Health Accelerate AI Trials"
              },
              {
                "id": 142882861,
                "url": "https://finnhub.io/api/news?id=93c15420dba820f73acdaf92c76e738f90d3f27ffc0b3533e13299a950b32e2a",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Morgan Stanley  analyst Ricky Goldwasser   maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $300 to $340.",
                "category": "company",
                "datetime": 1791894279,
                "headline": "Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $340"
              },
              {
                "id": 142847677,
                "url": "https://finnhub.io/api/news?id=cddde621353a46d82cf197be60342f9be17dd2d28c88a4b6ef3b00fae32ed5d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "WILMINGTON, Mass., October 13, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to support Magellan in the development and clinical advancement of its proprietary stem cell-based therapies and regenerative medicine solutions. The partnership will leverage Charles River’s specialized expertise in biologics quality control, current Good Manufacturing Practice (cGMP) viral and r",
                "category": "company",
                "datetime": 1791892800,
                "headline": "Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development"
              },
              {
                "id": 142849184,
                "url": "https://finnhub.io/api/news?id=cae78aa67d83366e974f3475b844be12c4846a61277b95a025a3a90fd39e09b6",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to support Magellan in the development and clinical",
                "category": "company",
                "datetime": 1791878667,
                "headline": "Charles River Laboratories International Partners With Magellan Stem Cells For Development, Clinical Advancement Of Stem Cell-Based Therapies, Regenerative Medicine Solutions"
              },
              {
                "id": 142821923,
                "url": "https://finnhub.io/api/news?id=53efda3451be265502610e54f2aac7d0c18c98fe0810a2e8a51f996620eccbf2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.",
                "category": "company",
                "datetime": 1791816423,
                "headline": "1 S&P 500 Stock to Target This Week and 2 We Question"
              },
              {
                "id": 142820380,
                "url": "https://finnhub.io/api/news?id=423149643bbad89b0db5f5911a4cddf6c995655e87d48181f8346bb1364ce1df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Boost ROI with AI-led design, automated high-throughput screening, customizable libraries, local production and diversified sourcing to cut costs and speed development.Dublin, Oct. 12, 2026 (GLOBE NEWSWIRE) -- \"Synthetic Antibody Library Global Market Report 2026\" has been added to ResearchAndMarkets.com's offering. The global synthetic antibody library market is experiencing rapid expansion, supported by rising demand for therapeutic antibodies, continued growth in biopharmaceutical research an",
                "category": "company",
                "datetime": 1791813600,
                "headline": "Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCellera"
              },
              {
                "id": 142760739,
                "url": "https://finnhub.io/api/news?id=9c7afb02e7e9d7abcc03d3cb0a983871d3e7356993eb8a452fb378da3b71b958",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "WILMINGTON, Mass., October 09, 2026--Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call",
                "category": "company",
                "datetime": 1791547200,
                "headline": "Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call"
              },
              {
                "id": 142730419,
                "url": "https://finnhub.io/api/news?id=5741fde32d2d428cfb091510e2b9dc970e9a9cdc9798a0a9de13df26fb600389",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "CRL",
                "summary": "Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1791477301,
                "headline": "Stay informed with the top movers within the S&P500 index on Thursday."
              },
              {
                "id": 142697487,
                "url": "https://finnhub.io/api/news?id=37c828691300a9de678d26bd8593aede8f0b62d682cd1ebd6b5c9150950f1f69",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "PGNY vs. CRL: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1791384004,
                "headline": "PGNY or CRL: Which Is the Better Value Stock Right Now?"
              },
              {
                "id": 142695289,
                "url": "https://finnhub.io/api/news?id=6a5ab641dfa540f4273e0bc7343b63546d8bed6db48b9a05cc96fc59a2885f95",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "CRL shares have surged 75.8% in a year as RMS trends improve, AI-enabled testing expands and cash flow supports buybacks and investment.",
                "category": "company",
                "datetime": 1791377460,
                "headline": "Charles River Gains 75.8% in a Year: What's Driving the Rally?"
              },
              {
                "id": 142665917,
                "url": "https://finnhub.io/api/news?id=96f2244ba53353df9f32cdb272b02c1bd237949d5c8d05b5b004c1bb61985f59",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "TFX's Vascular growth, Asia expansion and improved leverage support the outlook, but tariffs, input costs and margin pressure remain key risks.",
                "category": "company",
                "datetime": 1791296940,
                "headline": "Is It Prudent to Add Teleflex Stock to Your Portfolio Now?"
              },
              {
                "id": 142663488,
                "url": "https://finnhub.io/api/news?id=442468620f7300edd97e96030827e9ed4020cc52e307d09ca48212ba3f770b1d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "WILMINGTON, Mass. & LONDON, October 06, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) and Autolomous today announced the launch of Apollo Orchestrate™, a new capability within Charles River's Apollo® platform that connects and digitizes laboratory execution, built on Autolomous's autoloMATE® digital Laboratory Execution System (LES). The launch demonstrates continued progress on Charles River's strategic commitment to modernize and digitize laboratory workflows. Apollo® Orches",
                "category": "company",
                "datetime": 1791288000,
                "headline": "Charles River and Autolomous Partner to Transform Laboratory Execution Systems"
              },
              {
                "id": 142664252,
                "url": "https://finnhub.io/api/news?id=848f97ea160777aeb7ed35e35b75b28220a8868d46bf0b3145004ec3da03062c",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Partnership reinforces continued investment in digitization, automation, and client-facing transparencyCharles River Laboratories International, Inc. (NYSE:CRL) and Autolomous today announced the launch of Apollo",
                "category": "company",
                "datetime": 1791274390,
                "headline": "Charles River Laboratories and Autolomous Launch Apollo Orchestrate To Digitize Laboratory Execution Through autoloMATE Integration"
              },
              {
                "id": 142638288,
                "url": "https://finnhub.io/api/news?id=4796f000e83db0803c6b2ad30c002a2fc93fd2d01cc72622994706b14f78ea94",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "CRL",
                "summary": "Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Monday.",
                "category": "company",
                "datetime": 1791227101,
                "headline": "Uncover the latest developments among S&P500 stocks in today's session."
              },
              {
                "id": 142637485,
                "url": "https://finnhub.io/api/news?id=67961b010b1f3caecc8f221b133dc532a01b4d12e570aa9d8e37f37167ccb5a0",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "CRL",
                "summary": "Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Monday.",
                "category": "company",
                "datetime": 1791218101,
                "headline": "Which S&P500 stocks are moving on Monday?"
              },
              {
                "id": 142592897,
                "url": "https://finnhub.io/api/news?id=73d6aea502d0d31bd3b4f84722916a1926fcbb56cee537a66e1d38055c72cb31",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Price targets for Charles River Laboratories International have shifted higher in recent research, with several firms now pointing to a range between US$219 and US$340, alongside a new fair value estimate of US$305. That cluster of higher targets aligns with more constructive analyst commentary after the company’s investor and analyst days, as firms factor in the updated long range plan and revised margin goals. As you read on, you will see how to track these changes and what to watch as the...",
                "category": "company",
                "datetime": 1790967988,
                "headline": "Charles River Laboratories (CRL) Stock Fair Value Rises After Analyst Day Target Increases"
              },
              {
                "id": 142577515,
                "url": "https://finnhub.io/api/news?id=4004dabfc4e71581127dd887539a0ecf3abbbdbfca0c74f5d1873ab9ad91f51b",
                "image": "",
                "source": "Fintel",
                "related": "CRL",
                "summary": "",
                "category": "company",
                "datetime": 1790925229,
                "headline": "Charles River Laboratories International Consensus Price Target Increased by 11.46% to $307.39"
              },
              {
                "id": 142518422,
                "url": "https://finnhub.io/api/news?id=4f000e219b76905d0e4602a2357c480f40a8a0d43c3dffe4cc108d40fa5b5d11",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Animal model demand is rising with drug and vaccine research. CRISPR, AI and humanized models offer opportunities, while ethical scrutiny spurs humane alternatives.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- \"Animal Model - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering. The global animal model market was estimated at US$2.1 billion in 2025 and is projected to reach US$3.6 billion by 2032, advancing at a compound annual growth rate (CAGR) of 7.9%. Market exp",
                "category": "company",
                "datetime": 1790774880,
                "headline": "Animal Model - Global Strategic Business Report:  Market Size to Surge to $3.6 Billion by 2032 as CRISPR Disrupts R&D - Benchmark Charles River, Biocytogen, Crown Bioscience, Cyagen and The Jackson Laboratory"
              },
              {
                "id": 142517531,
                "url": "https://finnhub.io/api/news?id=4bd4d48cb235fd301171991d0bfe3cb1a9387d7e335c5a84377e0aab6d16e21c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Here is how Aveanna Healthcare (AVAH) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.",
                "category": "company",
                "datetime": 1790772002,
                "headline": "Is Aveanna Healthcare (AVAH) Stock Outpacing Its Medical Peers This Year?"
              },
              {
                "id": 142520420,
                "url": "https://finnhub.io/api/news?id=3bcdfc31b28a1e9d32bf937b1007a9d54474bac7dbab9269b99cd19feddf03cc",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 3.32% on an annualized basis producing an average annual return of 16.72%. Currently, Charles River has a market capitalization of $15.15",
                "category": "company",
                "datetime": 1790766039,
                "headline": "Here's How Much $1000 Invested In Charles River 15 Years Ago Would Be Worth Today"
              },
              {
                "id": 142520421,
                "url": "https://finnhub.io/api/news?id=cc0cb7255ec4f1bd0a5564f8462ab5a34a8f861a00590f3143b8ce54803c43bd",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "UBS  analyst Kevin Caliendo   reinstates Charles River (NYSE:CRL) with a Buy and announces $357 price target.",
                "category": "company",
                "datetime": 1790757739,
                "headline": "UBS Reinstates Buy on Charles River, Announces $357 Price Target"
              },
              {
                "id": 142499581,
                "url": "https://finnhub.io/api/news?id=7f51eba51258fdf6cd630123ee9af8f152c141f938e9c8148006d4aee3dc5cd2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Cooke & Bieler, an investment management firm, released its second-quarter investor letter for “Mid Cap Value Equity Strategy.” The letter can be downloaded here. U.S. equities rallied significantly in Q2, driven by shifting geopolitical risks and strong investor appetite for high-beta stocks, particularly in the tech sector, contributing to the S&P 500® and Nasdaq’s best […]",
                "category": "company",
                "datetime": 1790698275,
                "headline": "Demand Stabilization Fuels Charles River Laboratories International’s (CRL) Recovery"
              },
              {
                "id": 142498448,
                "url": "https://finnhub.io/api/news?id=33d389ce10e1c3a470a93edeb6350bbdab2e11354e2d65d66fcec4c7016e4514",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Stricter quality rules, complex biologics and outsourcing are driving demand for impurity isolation, synthesis and analytics, creating opportunities for specialized labs and CROs.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- \"Pharmaceutical Impurity Synthesis and Isolation Services - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering. The global pharmaceutical impurity synthesis and isolation services market was valued at US$1.3 billion in 2024 and is projected to",
                "category": "company",
                "datetime": 1790697120,
                "headline": "Pharmaceutical Impurity Synthesis and Isolation Services  Report: Capitalize on a $2.1 Billion Market by 2030 as Tariffs and 8.9% Isolation Growth Reshape Competition Across Eurofins, WuXi AppTec, Cambrex and Charles River"
              },
              {
                "id": 142498449,
                "url": "https://finnhub.io/api/news?id=b4e488f22dcd680cd9d6f1073f1177520302265edfe111909503cd1374c8c6fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "AI, machine learning, cloud analytics and multi-omics are accelerating drug discovery, enabling targeted, personalized therapies while reducing development time, cost and risk.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- \"Computer-Aided Drug Discovery - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering. The global computer-aided drug discovery market was estimated at US$3.2 billion in 2025 and is projected to reach US$6.7 billion by 2032, expanding at a compound",
                "category": "company",
                "datetime": 1790697060,
                "headline": "Computer-Aided Drug Discovery - Global Strategic Business Report: Capitalize on 11% CAGR as AI-led CADD surges from $3.2B in 2025 to $6.7B by 2032—benchmark Bayer, Charles River Laboratories, Pharmaron and Chemical Computing Group to secure growth."
              },
              {
                "id": 142495085,
                "url": "https://finnhub.io/api/news?id=1f13747f30781afd5effdb4cfed035abc4e598b4fd9cf0d20bc8009c926b865a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Engagement of a leading global contract research organization strengthens the analytical foundation supporting EL-22 and EL-32 as the programs advance toward an IND-enabling development frameworkBuilds on NorthStrive Biosciences’ expanding manufacturing and characterization capabilities behind its engineered probiotic platform targeting muscle preservation, including for patients on GLP-1 weight loss treatments NEWPORT BEACH, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq:",
                "category": "company",
                "datetime": 1790681580,
                "headline": "NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs"
              },
              {
                "id": 142487027,
                "url": "https://finnhub.io/api/news?id=23e5453460dd9e1f12da1cd9842974b512e65d80948df3cb7bb3f7e48175af39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Boost ROI by matching models to research goals, standardizing studies, investing in quality data and training, integrating validated AI and alternatives, and aligning global partnershipsDublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- \"Experimental Animal Model Market - Global Forecast 2026-2032\" has been added to ResearchAndMarkets.com's offering. This market research report examines the global Experimental Animal Model Market, which is projected to reach USD 1.31 billion in 2026 and expand at a comp",
                "category": "company",
                "datetime": 1790669220,
                "headline": "Global Experimental Animal Model Market Outlook and Forecast, 2026-2032 - AI-Enabled Research and Advanced Transgenic and Oncology Models Drive 9.18% CAGR Toward US$2.23 Billion, With Charles River, The Jackson Laboratory, Taconic Biosciences and Crown Bioscience Profiled"
              },
              {
                "id": 142467316,
                "url": "https://finnhub.io/api/news?id=da8b2e74678b76f253471de9bda93f56ad89236250cb85d9012c72196928a9af",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Jefferies  analyst David Windley   maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $305 to $340.",
                "category": "company",
                "datetime": 1790589930,
                "headline": "Jefferies Maintains Buy on Charles River, Raises Price Target to $340"
              },
              {
                "id": 142452869,
                "url": "https://finnhub.io/api/news?id=da87991122131ba1bc51d2b82e98e0e933eff651c52951f9b03cee7151f06fa8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories has outperformed the broader market over the past year, while analysts remain bullish on the company’s outlook.",
                "category": "company",
                "datetime": 1790542514,
                "headline": "Is Charles River Laboratories Stock Outperforming the S&P 500?"
              },
              {
                "id": 142431565,
                "url": "https://finnhub.io/api/news?id=bd97aef9c07a85a3b0403cde91733089cf1f386aa4a2a8a4ea3fdfb148209cae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International (NYSE:CRL) outlined a strategy to accelerate growth, expand margins and modernize its operations during its 2026 Investor Day, setting financial targets through 2030 that include 5% to 7% organic revenue growth, an approximately 24% non-GAAP operating margin",
                "category": "company",
                "datetime": 1790384521,
                "headline": "Charles River Targets 5%-7% Growth, $300M Savings in 2030 Plan"
              },
              {
                "id": 142438323,
                "url": "https://finnhub.io/api/news?id=f64902b156e51968f8472d757adea49fd6dfd43ab176c85ace2d79c66f2e31e8",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Deutsche Bank  analyst Justin Bowers   maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $300 to $320.",
                "category": "company",
                "datetime": 1790339347,
                "headline": "Deutsche Bank Maintains Buy on Charles River, Raises Price Target to $320"
              },
              {
                "id": 142422937,
                "url": "https://finnhub.io/api/news?id=503eae205e8311b47407630a099d37c1ebc08fcac9e74631bad61f49ef982ae9",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "TD Cowen  analyst Charles Rhyee   maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $300 to $325.",
                "category": "company",
                "datetime": 1790331879,
                "headline": "TD Cowen Maintains Buy on Charles River, Raises Price Target to $325"
              },
              {
                "id": 142422938,
                "url": "https://finnhub.io/api/news?id=ea9efbffadd3510acdca4b68cee9fface3c802eb69248200128cada685ec337e",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Evercore ISI Group  analyst Ross Muken   maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $320 to $330.",
                "category": "company",
                "datetime": 1790331719,
                "headline": "Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $330"
              },
              {
                "id": 142422939,
                "url": "https://finnhub.io/api/news?id=c09b9bf609cd928c8d605fc1713b96f1cbf5334546fe74fd61fb7948c451b729",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "RBC Capital  analyst Ryan Halsted   maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $282 to $322.",
                "category": "company",
                "datetime": 1790329577,
                "headline": "RBC Capital Maintains Outperform on Charles River, Raises Price Target to $322"
              },
              {
                "id": 142422940,
                "url": "https://finnhub.io/api/news?id=93852949fe84b507c7dc838d6428a4e13e88285fa5fcf70009fcd7596169ffbe",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Barclays  analyst Luke Sergott   maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $300 to $330.",
                "category": "company",
                "datetime": 1790325141,
                "headline": "Barclays Maintains Overweight on Charles River, Raises Price Target to $330"
              },
              {
                "id": 142421440,
                "url": "https://finnhub.io/api/news?id=811cfc98c0f6098a703ed0ec518579d54e0410b864d8327c06e5f99fa9989ae3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254790315/image_2254790315.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "CRL",
                "summary": "Charles River Laboratories has doubled over the past year, outperforming despite regulatory and AI-related concerns. Click for this CRL stock update.",
                "category": "company",
                "datetime": 1790325014,
                "headline": "Charles River Laboratories: Positive Investor Day Is Fully Priced In"
              },
              {
                "id": 142422941,
                "url": "https://finnhub.io/api/news?id=e5066d348aed8e386edd6c90545afbca1b3488663b992a52f45b3b7b00cf631c",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Mizuho  analyst Ann Hynes   maintains Charles River (NYSE:CRL) with a Neutral and raises the price target from $264 to $295.",
                "category": "company",
                "datetime": 1790324119,
                "headline": "Mizuho Maintains Neutral on Charles River, Raises Price Target to $295"
              },
              {
                "id": 142422942,
                "url": "https://finnhub.io/api/news?id=9aede5f63a07646a47697cda4d6a9cc33dc8ca4ba5ec8eb1354c5334373c654a",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Baird  analyst Eric Coldwell   maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $291 to $334.",
                "category": "company",
                "datetime": 1790321165,
                "headline": "Baird Maintains Outperform on Charles River, Raises Price Target to $334"
              },
              {
                "id": 142414133,
                "url": "https://finnhub.io/api/news?id=f4295499197bd6a9de8d58c9c7c1374eb6f03327aba6b2783a0480cc9096195d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.",
                "category": "company",
                "datetime": 1790320680,
                "headline": "CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?"
              },
              {
                "id": 142402006,
                "url": "https://finnhub.io/api/news?id=42da75f3364248802af2056a822959beeb514891c450db0e2602056cc50c92c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International has seen its share price move sharply over the past year, and that kind of run naturally raises a question for you as an investor. Are the cash flows that the business can generate enough to support where the stock now trades? The stock has returned 102.3% over the past 12 months, which puts real pressure on the case that its current valuation can still be explained by its underlying cash generation. Recent moves to expand outsourced services in areas...",
                "category": "company",
                "datetime": 1790316582,
                "headline": "Charles River Laboratories (CRL) Stock Still Seems Reasonable Despite Rapid Cell Banking Launch"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 6,
            "negative_hits": 0,
            "positive_hits": 3,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 59,
            "discarded_article_count": 53
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 22.3,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 2.7,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": true,
            "vcp_score": 2.7,
            "vcp_reason": "波幅收縮(24.3%→16.4%)；跌縮量(近10日3日)；站上MA50；升放量(近10日2日)；Ready=Y；Confirm=Y",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 1117776.6666666667,
              "down_days": 4,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 1170800,
              "avg_vol_20": 1090805,
              "avg_vol_30": 1117776.6666666667,
              "range_pct_10": 0.16391110982424648,
              "range_pct_20": 0.19283666792135976,
              "range_pct_30": 0.24304369227205605,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.0474364288632494,
              "dist_to_20d_high": 0.016628200126084115,
              "down_shrink_days": 3,
              "breakout_level_20d": 351.20999,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.6744100548010484
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.8,
          "rsiKdjPoints": 3.2,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.3,
            "details": {
              "atrPct": 4.318151547615601,
              "turnoverUsdM": 283.997751,
              "liquidityPoints": 0.6,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.6,
          "stopLevels": {
            "symbol": "US.CRL",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 315.5428,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 3,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.5,
            "stop_loss_percent": 8.6,
            "take_profit_price": 389.1166,
            "target_multiplier": 2.2,
            "technical_strength": 2,
            "take_profit_percent": 12.7
          },
          "positionPoints": 1.3,
          "stopLossPoints": 1.2,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.470536624289239,
          "stopLossPercent": 8.636303095231202,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.CRL",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 78.57,
    "atr": {
      "atr": 14.9136,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 4.32
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 205.13
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "輕微流入",
      "score": 6,
      "value": 0.1459
    },
    "kdj": {
      "d": 65.73,
      "j": 103.19,
      "k": 78.22,
      "rule": "Cursor_18.24 K/D cross",
      "score": 6,
      "signal": "強金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "強資金流入",
      "score": 10,
      "value": 70.44
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 4925200,
      "recentSlope": 211330,
      "previousSlope": -232520
    },
    "rsi": 69.51,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 292.1032,
      "position": "SAR喺價下",
      "distancePct": 15.42,
      "previousTrend": "上升"
    },
    "ma50": 293.9442,
    "macd": {
      "macd": 12.610319102690653,
      "trend": "強烈看漲",
      "signal": 8.324515310907238,
      "histogram": 4.285803791783415
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 312.3599,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 22
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.75,
      "score": 2,
      "avgVolume": 1090005,
      "currentVolume": 822300
    },
    "derived": {
      "ma20": 306.652,
      "ma50": 293.9442,
      "prevClose": 339.66,
      "avgVolume10": 1185050,
      "avgVolume20": 1090005,
      "changePercent": 1.68,
      "avgVolumeForScore": 1090005
    },
    "ma_cross": {
      "ma20": 306.652,
      "ma50": 293.9442,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 304.0255,
      "prevMa50": 292.6622,
      "spreadPct": 4.32,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 273.3839,
      "upper": 339.9201,
      "position": "上半部"
    },
    "rsi_short": 81.56,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.75
    }
  }
}

{
  "close": 345.37,
  "volume": 822300,
  "changePercent": 1.68
}